Literature DB >> 10678984

Protection against candidiasis by an immunoglobulin G3 (IgG3) monoclonal antibody specific for the same mannotriose as an IgM protective antibody.

Y Han1, M H Riesselman, J E Cutler.   

Abstract

We previously reported that a liposome-mannan vaccine (L-mann) of Candida albicans induces production of mouse antibodies that protect against disseminated candidiasis and vaginal infection. Immunoglobulin M (IgM) monoclonal antibody (MAb) B6.1, specific for a C. albicans cell surface beta-1,2-mannotriose, protects mice against both infections. Another IgM MAb, termed B6, which is specific for a different cell surface mannan epitope, does not protect against disseminated candidiasis. The B6.1 epitope is displayed homogeneously over the entire cell surface, compared to a patchy distribution of the B6 epitope. To determine if protection is restricted to an IgM class of antibody, we tested an IgG antibody. MAb C3.1 was obtained from L-mann-immunized mice. By results of sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis, capture enzyme-linked immunosorbent assay, and immunodiffusion tests, MAb C3.1 is an IgG3 isotype. By epitope inhibition assays, we determined that MAb C3.1 is specific for same mannotriose as MAb B6. 1. As expected by the results of the inhibition assays, immunofluorescence microscopy showed that the C3.1 epitope is distributed on the yeast cell surface in a pattern identical to that of the B6.1 epitope. Kidney CFU and mean survival times of infected mice pretreated with MAb C3.1 indicated that the antibody enhanced resistance of mice against disseminated candidiasis. Mice in pseudoestrus that were given MAb C3.1 prior to vaginal infection developed fewer vaginal Candida CFU than control animals that received buffered saline instead of the antibody. The finding that an IgG3 antibody is protective is consistent with our hypothesis that epitope specificity and complement activation are related to the ability of an antibody to protect against candidiasis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10678984      PMCID: PMC97325          DOI: 10.1128/IAI.68.3.1649-1654.2000

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  25 in total

Review 1.  Intermolecular cooperativity: a clue to why mice have IgG3?

Authors:  N S Greenspan; L J Cooper
Journal:  Immunol Today       Date:  1992-05

Review 2.  Antibody immunity and invasive fungal infections.

Authors:  A Casadevall
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

3.  Monoclonal antibodies in the therapy of experimental neonatal group B streptococcal disease.

Authors:  H R Hill; D K Kelsey; L A Gonzales; H V Raff
Journal:  Clin Immunol Immunopathol       Date:  1992-01

4.  Antibodies elicited by a Cryptococcus neoformans-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection.

Authors:  A Casadevall; J Mukherjee; S J Devi; R Schneerson; J B Robbins; M D Scharff
Journal:  J Infect Dis       Date:  1992-06       Impact factor: 5.226

5.  Characterisation of mouse monoclonal antibodies produced by immunisation with a single serotype component of a polyvalent Pseudomonas aeruginosa vaccine.

Authors:  G R Barclay; P L Yap; D B McClelland; R J Jones; E A Roe; M C McCann; L R Micklem; K James
Journal:  J Med Microbiol       Date:  1986-02       Impact factor: 2.472

6.  Characterization of monoclonal antibodies protecting mice against Rickettsia rickettsii.

Authors:  R L Anacker; R H List; R E Mann; S F Hayes; L A Thomas
Journal:  J Infect Dis       Date:  1985-06       Impact factor: 5.226

7.  Sequential nuclear magnetic resonance assignment of beta-1,2-linked mannooligosaccharides isolated from the phosphomannan of the pathogenic yeast Candida albicans NIH B-792 strain.

Authors:  N Shibata; K Hisamichi; T Kikuchi; H Kobayashi; Y Okawa; S Suzuki
Journal:  Biochemistry       Date:  1992-06-23       Impact factor: 3.162

8.  Structural identification of an epitope of antigenic factor 5 in mannans of Candida albicans NIH B-792 (serotype B) and J-1012 (serotype A) as beta-1,2-linked oligomannosyl residues.

Authors:  N Shibata; M Arai; E Haga; T Kikuchi; M Najima; T Satoh; H Kobayashi; S Suzuki
Journal:  Infect Immun       Date:  1992-10       Impact factor: 3.441

9.  Variable region-identical monoclonal antibodies of different IgG subclass directed to Pseudomonas aeruginosa lipopolysaccharide O-specific side chain function differently.

Authors:  J R Schreiber; L J Cooper; S Diehn; P A Dahlhauser; M F Tosi; D D Glass; M Patawaran; N S Greenspan
Journal:  J Infect Dis       Date:  1993-01       Impact factor: 5.226

10.  Subclass restriction of murine anti-carbohydrate antibodies.

Authors:  R M Perlmutter; D Hansburg; D E Briles; R A Nicolotti; J M Davie
Journal:  J Immunol       Date:  1978-08       Impact factor: 5.422

View more
  48 in total

1.  Vaccine and monoclonal antibody that enhance mouse resistance to candidiasis.

Authors:  Hong Xin; Jim E Cutler
Journal:  Clin Vaccine Immunol       Date:  2011-08-10

2.  Hybridoma passage in vitro may result in reduced ability of antimannan antibody to protect against disseminated candidiasis.

Authors:  Hong Xin; Jim E Cutler
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

3.  Design of a mimotope-peptide based double epitope vaccine against disseminated candidiasis.

Authors:  Hong Xin; Pati Glee; Abby Adams; Farhan Mohiuddin; Karen Eberle
Journal:  Vaccine       Date:  2019-03-28       Impact factor: 3.641

Review 4.  Anticandidal immunity and vaginitis: novel opportunities for immune intervention.

Authors:  Antonio Cassone; Flavia De Bernardis; Giorgio Santoni
Journal:  Infect Immun       Date:  2007-06-11       Impact factor: 3.441

Review 5.  Discovery of protective B-cell epitopes for development of antimicrobial vaccines and antibody therapeutics.

Authors:  Jacqueline Sharon; Michael J Rynkiewicz; Zhaohua Lu; Chiou-Ying Yang
Journal:  Immunology       Date:  2014-05       Impact factor: 7.397

6.  Monoclonal antibody to fungal glucosylceramide protects mice against lethal Cryptococcus neoformans infection.

Authors:  Marcio L Rodrigues; Li Shi; Eliana Barreto-Bergter; Leonardo Nimrichter; Sandra E Farias; Elaine G Rodrigues; Luiz R Travassos; Joshua D Nosanchuk
Journal:  Clin Vaccine Immunol       Date:  2007-08-22

7.  Biological activities of naturally occurring antibodies reactive with Candida albicans mannan.

Authors:  Thomas R Kozel; Randall S MacGill; Ann Percival; Qing Zhou
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

Review 8.  Immunopathogenesis of oropharyngeal candidiasis in human immunodeficiency virus infection.

Authors:  Louis de Repentigny; Daniel Lewandowski; Paul Jolicoeur
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

Review 9.  Surface glycans of Candida albicans and other pathogenic fungi: physiological roles, clinical uses, and experimental challenges.

Authors:  James Masuoka
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

10.  Candida-specific antibodies during experimental vaginal candidiasis in mice.

Authors:  Karen L Wozniak; Floyd L Wormley; Paul L Fidel
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.